NSCLC metastatic/molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 27/03/2020)

EGFR
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.

ALK
Currently no trials

KRAS
Currently no trials

RET
Currently no trials

BRAF
LXH254, LTT462 (Novartis)
A Phase Ib, open-label, multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer. (only cohort for BRAF open)

C-MET
Currently no trials

ROS1
BFAST (Roche)
A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial).
(only cohort D open)

HER2
ZENITH20 Poziotinib (Spectrum)
A Phase 2 Study of Poziotinib in Patients with Non-small cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation.